We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | 장 마감 후 (AMC) | $1.06 | — | — | $60.9M | — | 예정 |
| FY2025 Q3 | 2024. 12. 31. | 시각 미정 | — | $0.94 | — | — | $178.84M | 보고됨 |
| FY2025 Q2 | 2024. 09. 30. | 시각 미정 | — | $1.25 | — | — | $116M |
Consensus PT $104.5 · 2 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 02. 04. | Wells Fargo | — | 의견 유지 | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2025. 12. 16. | Wells Fargo | — | 의견 유지 | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q1 | 2024. 06. 30. | 시각 미정 | — | $0.62 | — | — | $58.17M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Stored first · Google News · Yahoo Finance (English)
Mesa Laboratories (MLAB) Slips 1.05% as Stock Nears Support Zone - Stock Buy Zone - thelegaladvocate.com
Mesa Laboratories (MLAB) Slips 1.05% as Stock Nears Support Zone - Stock Buy Zone thelegaladvocate.com
Mesa Labs 4Q Rev $63.7M >MLAB - Moomoo
Mesa Labs 4Q Rev $63.7M >MLAB Moomoo
Mesa Laboratories (MLAB) Profit Turnaround Tests Justification For Rich 74x P/E Multiple - simplywall.st
Mesa Laboratories (MLAB) Profit Turnaround Tests Justification For Rich 74x P/E Multiple simplywall.st
Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today
Mesa Labs: Fiscal Q4 Earnings Snapshot
Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results